<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Inst Med Trop Sao Paulo</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev. Inst. Med. Trop. Sao Paulo</journal-id>
      <journal-title-group>
        <journal-title>Revista do Instituto de Medicina Tropical de S&#xE3;o Paulo</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0036-4665</issn>
      <issn pub-type="epub">1678-9946</issn>
      <publisher>
        <publisher-name>Instituto de Medicina Tropical</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24879006</article-id>
      <article-id pub-id-type="pmc">4085857</article-id>
      <article-id pub-id-type="doi">10.1590/S0036-46652014000300013</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>USE OF LOPINAVIR/RITONAVIR ASSOCIATED WITH ERGOTAMINE RESULTING IN FOOT
AMPUTATION: BRIEF COMMUNICATION</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Uso de lopinavir/ritonavir associado com ergotamina resultando em
amputa&#xE7;&#xE3;o de p&#xE9;: comunica&#xE7;&#xE3;o breve</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ferry</surname>
            <given-names>Fernando Raphael de Almeida</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Guilherme Almeida Rosa Da</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Motta</surname>
            <given-names>Rogerio Neves</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carvalho</surname>
            <given-names>Ricardo de Souza</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>S&#xE1;</surname>
            <given-names>Carlos Alberto Morais De</given-names>
          </name>
          <xref ref-type="aff" rid="aff1"/>
        </contrib>
        <aff id="aff1"> UNIRIO, Rio de Janeiro, RJ, <country>Brazil</country>. E-mails:
<email>ferry@unirio.br</email><email>drguialmeida@gmail.com</email><email>nevesmotta@gmail.com</email><email>ricardocarvalho@gmail.com</email><email>carlosalberto@gmail.com</email></aff>
      </contrib-group>
      <author-notes>
        <corresp><bold>Correspondence to:</bold> Guilherme Almeida Rosa da Silva, Hospital
Universit&#xE1;rio Gaffr&#xE9;e e Guinle, Universidade Federal do Estado do Rio de Janeiro, 10&#xAA;
Enfermaria, Rua Mariz e Barros 775, Tijuca, Rio de Janeiro, RJ, Brasil. Tel.
+55.21.81868189.</corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2014</year>
      </pub-date>
      <volume>56</volume>
      <issue>3</issue>
      <fpage>265</fpage>
      <lpage>266</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>8</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>10</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p id="para1">A 32-year-old female, was diagnosed in 2004 with a C1 HIV1 infection,
using zidovudine/lamivudine 300/150 mg BID and lopinavir/ritonavir 400/100 mg BID, in
addition to prophylaxis with trimethoprim-sulfamethoxazole 800/160 mg QD, but no
prophylaxis with macrolide antibiotics. The patient presented with a severe headache
and was prescribed two capsules of the anti-migraine drug Ormigrein&#x2122;, which contained
ergotamine tartrate 1 mg, caffeine 100 mg, paracetamol 220 mg, hyoscyamine sulfate
87.5 mcg, and atropine sulfate 12.5 mcg. Afterwards she was prescribed one capsule of
Ormigrein every 30 minutes for a total of six capsules a day. The patient took the
medication as prescribed but developed a pain in her left ankle three days later,
which evolved to the need for amputation.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p id="para2">Mulher de 32 anos infectada pelo HIV 1, vinha utilizando
zidovudina/lamivudina 300/150 mg um comprimido duas vezes ao dia e
lopinavir/ritonavir 200/50 mg dois comprimidos duas vezes ao dia e profilaxia com
sulfametoxazol-trimetoprim 800/160 mg uma vez ao dia, sem profilaxia com macrol&#xED;deos.
A paciente apresentou enxaqueca severa com prescri&#xE7;&#xE3;o da associa&#xE7;&#xE3;o tartarato de
ergotamina 1 mg, cafe&#xED;na 100 mg, paracetamol 220 mg, sulfato de hiosciamina 87,5 mcg,
sulfato de atropina 12,5 mcg, dois comprimidos na crise, seguido de um comprimido a
cada 30 minutos, com no m&#xE1;ximo seis comprimidos ao dia. A paciente ingeriu seis
comprimidos em um dia, surgindo uma dor em tornozelo esquerdo tr&#xEA;s dias depois, que
evoluiu para ergotismo e amputa&#xE7;&#xE3;o do p&#xE9;.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>AIDS</kwd>
        <kwd>Ritonavir</kwd>
        <kwd>Antiretroviral</kwd>
        <kwd>Pharmacological interactions</kwd>
      </kwd-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="0"/>
        <ref-count count="5"/>
        <page-count count="2"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <p id="para3">MLS, a 32-year-old female, was diagnosed in 2004 with a C1 HIV1 infection
(Centers for Disease Control classification). She discontinued her antiretroviral therapy
(zidovudine, lamivudine and nevirapine) two years after starting the treatment and
presented with the clinical manifestations of fever, dyspnea, appetite loss, diarrhea,
anemia, weight loss, and severe asthenia. Her chest X-ray, arterial blood gases and lactate
dehydrogenase levels were suggestive of pulmonary pneumocystis. Oral and vaginal
candidiasis were also observed. She exhibited a good clinical response to treatment with
trimethoprim-sulfamethoxazole, fluconazole, corticosteroid and symptomatic drugs. We
reintroduced highly active antiretroviral therapy (HAART) with zidovudine/lamivudine
300/150 mg BID and lopinavir/ritonavir 400/100 mg BID, in addition to prophylaxis with
trimethoprim-sulfamethoxazole 800/160 mg QD, but no prophylaxis with macrolide antibiotics.
Three weeks later, the patient presented with a severe headache at another institution,
where physicians were not well trained in the management of AIDS patients. During the
crisis, the patient was prescribed two capsules of the anti-migraine drug Ormigrein&#x2122;, which
contained ergotamine tartrate 1 mg, caffeine 100 mg, paracetamol 220 mg, hyoscyamine
sulfate 87.5 mcg, and atropine sulfate 12.5 mcg. Afterwards she was prescribed one capsule
of Ormigrein every 30 minutes for a total of six capsules a day. The patient took the
medication as prescribed but developed pain in her left ankle three days later, which she
self-treated with NSAIDs and a local application of ice.</p>
    <p id="para4">As the symptoms worsened, she was admitted to our Hospital Medical AIDS Center.
Her left lower limb on admission was cyanotic with cold, clammy skin and an absence of
palpable pedal pulses. She was treated with an intra-arterial prostaglandin injection,
followed by a synthetic prostaglandin analog given intravenously and sildenafil given by
mouth, but only had a partial clinical response. Due to the ischemia of the distal vessels
in her lower extremity and the necrosis of her left toes, a foot amputation at the
metatarsal level was performed.<sup><xref rid="B04" ref-type="bibr">4</xref></sup>
</p>
    <p id="para5">Ritonavir is an anti-HIV protease inhibitor that was approved by the FDA in
March of 1996. <italic>In vitro</italic> studies utilizing human liver microsomes
demonstrated that major cytochrome P450 isoforms, mainly CYP3A4, CYP2D6 and CYP2C9/10, were
involved in the metabolism of ritonavir. Currently, ritonavir is no longer used alone as a
protease inhibitor in antiretroviral regimens. This drug is used in combination with
lopinavir or another antiretroviral agent to increase the plasma levels of antiretroviral
drugs by cytochrome inhibition[1,2.]</p>
    <p id="para6">Thus, the reduction of the daily dose of ritonavir to 100-200 mg/day was
recommended in combination with regimens. In the protease inhibitor combination
lopinavir/ritonavir, the dose of ritonavir 200 mg daily is enough to increase plasma levels
of lopinavir significantly. Therefore, caution is recommended when ritonavir is used in
antiretroviral regimens, because coadministration with other drugs may be jeopardized on
account of ritonavir competition for CYP3A4.</p>
    <p id="para7">Ergotamine derivatives have partial agonist and antagonist activity against
tryptaminergic, dopaminergic and alpha-adrenergic receptors, depending upon their binding
site. Serious vasospasm and ischemia of the extremities and other tissues including the CNS
have been observed with ergotamine derivatives.</p>
    <p id="para8">The main indication of ergotamine is for the treatment of vascular headaches
(migraine, migraine variants and histaminic cephalalgia). The effect of ergotamine may be
potentiated by the concomitant use of drugs that inhibit the metabolism of cytochrome P450
3A4, such as ritonavir. The interaction of ergotamine with ritonavir has already been reported<sup><xref rid="B01" ref-type="bibr">1</xref>,<xref rid="B03" ref-type="bibr">3</xref></sup>, especially in cases when the daily dose of ritonavir reaches 1200 mg. In 2002,
there was a report of a fatal case of ergot toxicity with ritonavir 200 mg daily, in which
a combination of ergotamine with an antiretroviral regimen of stavudine, lamivudine and
indinavir/ritonavir caused serious peripheral and cerebral vasoconstriction<sup><xref rid="B05" ref-type="bibr">5</xref></sup>.</p>
    <p>
<fig id="f01" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>
<bold>A</bold> - (Up and down) Left lower limb with cyanosis, necrosis, edema, and
clammy skin. <bold>B</bold> - (Up and down) Left foot amputation at the metatarsal
level.</title></caption><graphic xlink:href="0036-4665-rimtsp-56-03-265-gf01"/></fig>
</p>
  </body>
  <back>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caballero-Granado</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Viciana</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Cordero</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Gomez-Vera</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>del Nozal</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lopez-Cortes</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
          <article-title>Ergotism related to concurrent administration of
ergotamine tartrate and ritonavir in an AIDS patient</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>1997</year>
          <volume>41</volume>
          <fpage>1207</fpage>
          <pub-id pub-id-type="pmid">9145904</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>GN</given-names>
            </name>
            <name>
              <surname>Rodrigues</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Buko</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Denissen</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Cytochrome P450-mediated metabolism of the HIV-1
protease inhibitor ritonavir (ABT-538) in human liver microsomes</article-title>
          <source>J Pharmacol Exp Ther</source>
          <year>1996</year>
          <volume>277</volume>
          <fpage>423</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">8613951</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liaudet</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Buclin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Jaccard</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Eckert</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Drug points: severe ergotism associated with interaction
between ritonavir and ergotamine</article-title>
          <source>BMJ</source>
          <year>1999</year>
          <volume>318</volume>
          <fpage>771</fpage>
          <pub-id pub-id-type="pmid">10082701</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marine</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Enriquez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Greig</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sanhueza</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Mertens</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Four-limb acute ischemia induced by ergotamine in an
AIDS patient treated with protease inhibitors</article-title>
          <source>Circulation</source>
          <year>2011</year>
          <volume>124</volume>
          <fpage>1395</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">21931103</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tribble</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Gregg</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Margolis</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Amirkhan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Fatal ergotism induced by an HIV protease
inhibitor</article-title>
          <source>Headache</source>
          <year>2002</year>
          <volume>42</volume>
          <fpage>694</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">12482227</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
